Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: Final analysis of the GAUSS study

Journal of Clinical Oncology

Volumn 33, Issue 30, 2015, Pages 3467-3474

  Sehn, Laurie H ^a   Goy, Andre ^a   Offner, Fritz C ^e   Martinelli, Giovanni ^f   Caballero, M Dolores ^h   Gadeberg, Ole ⁱ   Baetz, Tara ^b   Zelenetz, Andrew D ^d,j   Gaidano, Gianluca ^g   Fayad, Luis E ^d   Buckstein, Rena ^c   Friedberg, Jonathan W ^k   Crump, Michael ^c   Jaksic, Branimir ^l   Zinzani, Pier Luigi ^e   Iyer, Swaminathan Padmanabhan ^m   Sahin, Deniz ⁿ   Chai, Akiko ^o   Fingerle Rowson, Günter ⁿ   Press, Oliver W ^p  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ LILLEBAELT HOSPITAL   (Denmark)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^l University of Zagreb   (Croatia)

^m WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁿ F HOFFMANN LA ROCHE LTD   (Switzerland)

^o GENENTECH INC   (United States)

^p Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; OBINUTUZUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRALGIA; ASTHENIA; BACKACHE; BRONCHITIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; HYPERTENSION; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SINUSITIS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; BIOSYNTHESIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA, B-CELL; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RITUXIMAB;

EID: 84944960445     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.2139     Document Type: Conference Paper

References (41)

1. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
2. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
3. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
4. Robak T, Dmoszynska A, Solal-Céligny P, et al: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756-1765, 2010
5. van Oers MH, Van Glabbeke M, Giurgea L, et al: Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Longterm outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28:2853-2858, 2010
6. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033, 2005
7. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
8. Salles G, Seymour JF, Offner F, et al: Ritux-imab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
9. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 112:4824-4831, 2008
10. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004
11. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007
12. Schulz H, Bohlius JF, Trelle S, et al: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst 99:706-714, 2007
13. Hainsworth JD, Litchy S, Barton JH, et al: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746-1751, 2003
14. Davis TA, White CA, Grillo-López AJ, et al: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. J Clin Oncol 17:1851-1857, 1999
15. Davis TA, Grillo-López AJ, White CA, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143, 2000
16. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
17. Piro LD, White CA, Grillo-López AJ, et al: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10: 655-661, 1999
18. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004
19. Hochster H, Weller E, Gascoyne RD, et al: Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study. J Clin Oncol 27:1607-1614, 2009
20. Chan HT, Hughes D, French RR, et al: CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 63:5480-5489, 2003
21. Cragg MS, Glennie MJ: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103:2738-2743, 2004
22. Glennie MJ, French RR, Cragg MS, et al: Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44:3823-3837, 2007
23. Niederfellner G, Lammens A, Mundigl O, et al: Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 118: 358-367, 2011
24. Ivanov A, Beers SA, Walshe CA, et al: Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 119:2143-2159, 2009
25. Alduaij W, Illidge TM: The future of anti-CD20 monoclonal antibodies: Are we making progress? Blood 117:2993-3001, 2011
26. Alduaij W, Ivanov A, Honeychurch J, et al: Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117:4519-4529, 2011
27. Mössner E, Brünker P, Moser S, et al: Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cellmediated B-cell cytotoxicity. Blood 115:4393-4402, 2010
28. Dalle S, Reslan L, Besseyre de Horts T, et al: Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 10:178-185, 2011
29. Patz M, Isaeva P, Forcob N, et al: Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 152:295-306, 2011
30. Salles G, Morschhauser F, Lamy T, et al: Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119:5126-5132, 2012
31. Sehn LH, Assouline SE, Stewart DA, et al: A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 119:5118-5125, 2012
32. Salles GA, Morschhauser F, Solal-Céligny P, et al: Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: Results from the phase II GAUGUIN study. J Clin Oncol 31:2920-2926, 2013
33. Morschhauser FA, Cartron G, Thieblemont C, et al: Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: Results from the phase II GAUGUIN study. J Clin Oncol 31:2912-2919, 2013
34. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
35. Klein C, Lammens A, Schäfer W, et al: Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 5:22-33, 2013
36. Blanco-Toribio A, Sainz-Pastor N, Álvarez-Cienfuegos A, et al: Generation and characterization of monospecific and bispecific hexavalent trimerbodies. MAbs 5:70-79, 2013
37. Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F, et al: Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: A single institution case control study. Leuk Lymphoma 51:399-405, 2010
38. Goede V, Fischer K, Busch R, et al: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101-1110, 2014
39. Gordan LN, Grow WB, Pusateri A, et al: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23:1096-1102, 2005
40. Maloney DG, Grillo-López AJ, Bodkin DJ, et al: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997
41. Winkler U, Jensen M, Manzke O, et al: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94:2217-2224, 1999